CHEBI:49375 - dasatinib (anhydrous)

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name dasatinib (anhydrous)
ChEBI ID CHEBI:49375
Definition An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).
Stars This entity has been manually annotated by the ChEBI Team.
Secondary ChEBI IDs CHEBI:38943, CHEBI:49372
Supplier Information
Download Molfile XML SDF
more structures >>
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C22H26ClN7O2S
Net Charge 0
Average Mass 488.00652
Monoisotopic Mass 487.15572
InChI InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
InChIKey ZBNZXTGUTAYRHI-UHFFFAOYSA-N
SMILES Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): anticoronaviral agent
Any antiviral agent which inhibits the activity of coronaviruses.
tyrosine kinase inhibitor
Any protein kinase inhibitor that interferes with the action of tyrosine kinase.
Application(s): antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing dasatinib (anhydrous) (CHEBI:49375) has role anticoronaviral agent (CHEBI:149553)
dasatinib (anhydrous) (CHEBI:49375) has role antineoplastic agent (CHEBI:35610)
dasatinib (anhydrous) (CHEBI:49375) has role tyrosine kinase inhibitor (CHEBI:38637)
dasatinib (anhydrous) (CHEBI:49375) is a 1,3-thiazoles (CHEBI:38418)
dasatinib (anhydrous) (CHEBI:49375) is a N-(2-hydroxyethyl)piperazine (CHEBI:46851)
dasatinib (anhydrous) (CHEBI:49375) is a N-arylpiperazine (CHEBI:46848)
dasatinib (anhydrous) (CHEBI:49375) is a aminopyrimidine (CHEBI:38338)
dasatinib (anhydrous) (CHEBI:49375) is a monocarboxylic acid amide (CHEBI:29347)
dasatinib (anhydrous) (CHEBI:49375) is a organochlorine compound (CHEBI:36683)
dasatinib (anhydrous) (CHEBI:49375) is a secondary amino compound (CHEBI:50995)
dasatinib (anhydrous) (CHEBI:49375) is a tertiary amino compound (CHEBI:50996)
dasatinib (anhydrous) (CHEBI:49375) is conjugate base of dasatinib(1+) (CHEBI:190514)
Incoming dasatinib monohydrate (CHEBI:70839) has part dasatinib (anhydrous) (CHEBI:49375)
dasatinib(1+) (CHEBI:190514) is conjugate acid of dasatinib (anhydrous) (CHEBI:49375)
IUPAC Name
N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
INNs Sources
dasatinib WHO MedNet
dasatinib WHO MedNet
dasatinib
Note: (2012-11-05) Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).
 WHO MedNet
dasatinibum WHO MedNet
Synonyms Sources
anh. dasatinib ChEBI
anhydrous dasatinib ChEBI
BMS Dasatinib ChEBI
BMS-354825 ChEBI
dasatinib (anh.) ChEBI
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE PDBeChem
Manual Xrefs Databases
1N1 PDBeChem
785 DrugCentral
D03658 KEGG DRUG
Dasatinib Wikipedia
DB01254 DrugBank
HMDB0015384 HMDB
LSM-1020 LINCS
US7125875 Patent
US7941725 Patent
WO2010067374 Patent
WO2010139979 Patent
View more database links
Registry Numbers Types Sources
302962-49-8 CAS Registry Number ChemIDplus
9966762 Reaxys Registry Number Reaxys
Citations Waiting for Citations Types Sources
16775234 PubMed citation Europe PMC
17154512 PubMed citation Europe PMC
18020922 PubMed citation Europe PMC
18784745 PubMed citation Europe PMC
18797457 PubMed citation Europe PMC
18823558 PubMed citation Europe PMC
19494352 PubMed citation Europe PMC
19502192 PubMed citation Europe PMC
19640584 PubMed citation Europe PMC
21226671 PubMed citation Europe PMC
22411867 PubMed citation Europe PMC
22740998 PubMed citation Europe PMC
22992064 PubMed citation Europe PMC
23065516 PubMed citation Europe PMC
Last Modified
30 March 2022
General Comments
2012-11-05 .
2012-11-05 .